Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?

B. Brett Finlay; Romina Goldszmid; Kenya Honda; Giorgio Trinchieri; Jennifer Wargo; Laurence Zitvogel

doi:10.1038/s41577-020-0374-6

Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?

B. Brett Finlay, Romina Goldszmid, Kenya Honda, Giorgio Trinchieri, Jennifer Wargo, Laurence Zitvogel

Department of Microbiology and Immunology

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

There is currently much interest in defining how the microbiota shapes immune responses in the context of cancer. Various studies in both mice and humans have associated particular commensal species with better (or worse) outcomes in different cancer types and following treatment with cancer immunotherapies. However, the mechanisms involved remain ill-defined and even controversial. In this Viewpoint, Nature Reviews Immunology has invited six eminent scientists in the field to share their thoughts on the key questions and challenges for the field.

Original language	English
Pages (from-to)	522-528
Number of pages	7
Journal	Nature Reviews Immunology
Volume	20
Issue number	9
DOIs	https://doi.org/10.1038/s41577-020-0374-6
Publication status	Published - 2020 Sep 1

ASJC Scopus subject areas

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1038/s41577-020-0374-6

Fingerprint Dive into the research topics of 'Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?'. Together they form a unique fingerprint.

Cite this

@article{b853408a396c4bf49c89e956ba4bedbf,

title = "Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?",

abstract = "There is currently much interest in defining how the microbiota shapes immune responses in the context of cancer. Various studies in both mice and humans have associated particular commensal species with better (or worse) outcomes in different cancer types and following treatment with cancer immunotherapies. However, the mechanisms involved remain ill-defined and even controversial. In this Viewpoint, Nature Reviews Immunology has invited six eminent scientists in the field to share their thoughts on the key questions and challenges for the field.",

author = "Finlay, {B. Brett} and Romina Goldszmid and Kenya Honda and Giorgio Trinchieri and Jennifer Wargo and Laurence Zitvogel",

note = "Funding Information: K.H. was funded through AMED LEAP under grant number JP18gm0010003. R.G. is supported by the Intramural Research Program of the US National Institutes of Health, National Cancer Institute. The L.Z. laboratory is supported by RHU Torino Lumi{\`e}re (ANR-16-RHUS-0008), the ONCOBIOME project (European Union Horizon 2020 programme), the Seerave Foundation, the French Agence Nationale de la Recherche (Ileobiome), the French Ligue Contre le Cancer ({\'E}quipe Labelis{\'e}es programme), the French Association pour la Recherche sur le Cancer, Canc{\'e}rop{\^o}le Ile-de-France, the French Fondation pour la Recherche M{\'e}dicale, a donation by Elior and Dassault Systems, the European Research Council, Fondation Carrefour, the French Institut National du Cancer INSERM (HTE programme), LabEx Immuno-Oncology, SIRIC Stratified Oncology Cell DNA Repair and Tumour Immune Elimination (SOCRATE) and the CARE network (directed by X. Mariette, Assistance Publique — H{\^o}pitaux de Paris, Kremlin-Bic{\^e}tre). Publisher Copyright: {\textcopyright} 2020, Springer Nature Limited.",

year = "2020",

month = sep,

day = "1",

doi = "10.1038/s41577-020-0374-6",

language = "English",

volume = "20",

pages = "522--528",

journal = "Nature Reviews Immunology",

issn = "1474-1733",